SCHEMBL1806371

SCHEMBL1806371

CCCn1[nH]c(=O)c2cc(NS(=O)(=O)c3cccc(Cl)c3Cl)ccc21

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 8/20 0.49
ALDH1A1 P00352 3/20 0.48
LMNA P02545 2/20 0.46
GHSR Q92847 1/20 0.45
SGK1 O00141 1/20 0.44
BRD4 O60885 2/20 0.43
NR1I2 O75469 1/20 0.43
PTGES2 Q9H7Z7 2/20 0.43
PGR P06401 1/20 0.42
MEN1 O00255 1/20 0.42
THRB P10828 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1809645 0.85 PTGES2 (0.46) CCR4ALDH1A1LMNAGHSRSGK1
SCHEMBL3916206 0.83 BRD4 (0.52) LMNASGK1BRD4NR1I2MEN1
SCHEMBL3906958 0.82 LMNA (0.46) ALDH1A1LMNABRD4NR1I2MEN1
SCHEMBL3906659 0.82 PTGES2 (0.47) CCR4ALDH1A1LMNAGHSRSGK1
SCHEMBL1818816 0.82 PTGES2 (0.42) CCR4ALDH1A1LMNAGHSRSGK1
SCHEMBL3917157 0.81 GSPT1 (0.42) CCR4ALDH1A1LMNABRD4NR1I2
SCHEMBL3904770 0.80 NR1I2 (0.43) ALDH1A1LMNABRD4NR1I2MEN1
SCHEMBL3908595 0.80 GSPT1 (0.42) CCR4ALDH1A1LMNASGK1BRD4
SCHEMBL3903058 0.79 GSPT1 (0.41) CCR4ALDH1A1LMNABRD4NR1I2
SCHEMBL1809464 0.79 PTGDR2 (0.49) ALDH1A1LMNAMEN1THRBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4682207-B2 2011-05-11 JP claimed
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US claimed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP claimed
EP-1797042-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2007-06-20 EP claimed
WO-2006034804-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-04-06 WO claimed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US claimed
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP disclosed
EP-1797042-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2007-06-20 EP disclosed
WO-2006034804-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-04-06 WO disclosed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors HSD17B1, HSD11B1, HSD17B7 CCR4 3826/4885ALDH1A1 62/4885LMNA 3419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.